Clinical trials: Glucagon
Diabetes Mellitus, Type 1
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.
- Trial name
- NCT02660242
- Testing
- G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes Mellitus
Artificial Pancreas Control System in an Outpatient Setting
The objectives of this outpatient research study are (1) to assess the ability of this automated system to be operated by a subject with limited professional oversight; (2) to assess whether the new devices (Dexcom Gen 4 sensors…
- Trial name
- NCT01871870
- Testing
- Artificial Pancreas Control Software
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Legacy Health System
Sleep Apnea, Sleep Disordered Breathing
A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
This is an open label, controlled study. The investigators are studying if the FDA approved diabetes medicine liraglutide (Victoza®) can improve sleep apnea in adults.
- Trial name
- NCT01832532
- Testing
- liraglutide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Congenital Hyperinsulinism
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy.
- Trial name
- NCT00835328
- Testing
- Exendin (9-39), Vehicle
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diva De Leon
Metabolic Syndrome
Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome
Glucagon-like peptide 1 (GLP-1) is an intestinal peptide hormone secreted in a nutrient-dependent manner that stimulates the pancreatic beta cells to secrete more insulin in response to the same amount of blood glucose.
- Trial name
- NCT00856700
- Testing
- GLP-1 infusion
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rome Tor Vergata
Obesity, Type 2 Diabetes
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM).
- Trial name
- LIBRA (NCT01363609)
- Testing
- Liraglutide treatment 12 weeks, insulin glargine treatment, GLP-1 receptor antagonist
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Heart Failure, Diabete Type 2
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1).
- Conditions
- Heart Failure, Diabete Type 2, Arterial Hypertension
- Trial name
- ICDDTKZ26 (NCT07303556)
- Testing
- Tirzepatide (Mounjaro), dapagliflozin, empagliflozin, metformin
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Nazarbayev University
Hyperinsulinemic Hypoglycemia
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial…
- Trial name
- NCT03770637
- Testing
- Glucagon RTU
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after…
- Trial name
- NCT06801015
- Testing
- Semaglutide, Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Acute Ischemic Stroke, Large Vessel Occlusion
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS.
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
- Trial name
- GALLOP2 (NCT06788626)
- Testing
- Semaglutide 0.5 mg, Standard medical treatment
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Wei Hu
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Delayed Gastric Emptying, Gastroparesis
Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.
Given the increased prescription of GLP-1 agonists for both diabetes and obesity management and the implications of the proposed delayed gastric emptying in the setting of an anesthetic, it is critical to determine if patients…
- Trial name
- NCT06038734
- Testing
- gastric ultrasound
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Coronary Artery Disease, Decreased Left Ventricular Function
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass
GLP-1 has not only beneficial effects on glucose metabolism but also direct positive effects on cardiac function and metabolism in both experimental models and in patients with type 2 diabetes mellitus.
- Trial name
- Executive (NCT01373216)
- Testing
- Exenatide
- Where
- Czechia
- Volunteers
- 38 people
- Sponsor
- Charles University, Czech Republic
Type 1 Diabetes, Hyperglycemia, Postprandial
Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9…
- Trial name
- NCT04079881
- Testing
- Insulin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Diabetes, Bariatric Surgery
Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery
Bariatric surgery can lead to improvement or even resolution of type 2 diabetes in about 80% of patients submitted to Roux-en-Y gastric bypass (RYGP).
- Conditions
- Diabetes, Bariatric Surgery, Obesity
- Trial name
- NCT00834938
- Testing
- No intervention
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.
- Trial name
- NCT02639130
- Testing
- Exendin [9-39]
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Gastric Bypass Surgery, Obesity
Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery
Analyze the effect of meal pattern (meal number, frequency, and form) on satiety, gut peptides, insulin, and glucose levels in individuals before and 12-15 months after gastric bypass surgery (GBP).
- Trial name
- NCT01938469
- Testing
- Liquid Meal, Solid Meal
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Intracranial Atherosclerosis, Stroke, Ischemic
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD.
- Trial name
- RADIANT (NCT07282041)
- Testing
- Dulaglutide
- Where
- Singapore
- Volunteers
- 130 people
- Sponsor
- National University of Singapore